Primary breast cancer cell culture yields intra-tumor heterogeneous subpopulations expressing exclusive patterns of receptor tyrosine kinases

[1]  G. Ren,et al.  Epithelial-mesenchymal transition and drug resistance in breast cancer (Review). , 2015, International journal of oncology.

[2]  S. Gurzu,et al.  Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update. , 2015, World journal of clinical cases.

[3]  A. Popel,et al.  Heterogeneity of chemokine cell-surface receptor expression in triple-negative breast cancer. , 2015, American journal of cancer research.

[4]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[5]  N. McGranahan,et al.  Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.

[6]  F. Beca,et al.  Tumor heterogeneity: the Lernaean hydra of oncology? , 2014, Oncology.

[7]  L. Stalker,et al.  Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors , 2014, Cancer Cell International.

[8]  J. Reis-Filho,et al.  Breast cancer intra-tumor heterogeneity , 2014, Breast Cancer Research.

[9]  N. Cherdyntseva,et al.  Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression , 2014, Scientific Reports.

[10]  H. Medina-Franco,et al.  Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells , 2013, Journal of Cancer Research and Clinical Oncology.

[11]  B. Berghuis,et al.  MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance , 2013, Molecular Cancer Research.

[12]  M. Duffy,et al.  Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours , 2012, Breast Cancer Research and Treatment.

[13]  K. Polyak,et al.  Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.

[14]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[15]  Jorge S Reis-Filho,et al.  Genetic heterogeneity and cancer drug resistance. , 2012, The Lancet. Oncology.

[16]  Paul Ellis,et al.  Dissecting the heterogeneity of triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Kornelia Polyak,et al.  Heterogeneity in breast cancer. , 2011, The Journal of clinical investigation.

[18]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[19]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[20]  F. Esteva,et al.  Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[21]  R. Schiff,et al.  Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. , 2008, Cancer research.

[22]  A. Vincent-Salomon,et al.  Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Charles M Perou,et al.  EGFR associated expression profiles vary with breast tumor subtype , 2007, BMC Genomics.

[24]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[25]  P. Ellis,et al.  Adjuvant trastuzumab for HER2-positive breast cancer , 2005, The Lancet.

[26]  Albino Martins,et al.  Overexpression of platelet-derived growth factor receptor α in breast cancer is associated with tumour progression , 2005, Breast Cancer Research.

[27]  K. Miyazaki,et al.  Expression of the hepatocyte growth factor/c‐Met pathway is increased at the cancer front in breast carcinoma , 2001, Pathology international.

[28]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[29]  Christian A. Rees,et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  E. Rimm,et al.  Expression of c‐met is a strong independent prognostic factor in breast carcinoma , 1998, Cancer.

[31]  B. Elliott,et al.  Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  A. Gown,et al.  Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. , 1995, Cancer research.

[33]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[34]  T. Tot,et al.  Molecular phenotype of the foci in multifocal invasive breast carcinomas: Intertumoral heterogeneity is related to shorter survival and may influence the choice of therapy , 2014, Cancer.

[35]  J. Troge,et al.  Inferring tumor progression from genomic heterogeneity. , 2010, Genome research.

[36]  L. Seymour,et al.  Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer , 2004, Breast Cancer Research and Treatment.

[37]  A. Gown,et al.  Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. , 1995, Cancer research.